Exploring the Functions of polymers in adenovirus-mediated gene delivery: evading immune response and redirecting tropism.

Adenovirus (Ad) is a promising viral carrier in gene therapy because of its unique attribution. However, clinical applications of Ad vectors are currently restricted by their immunogenicity and broad native tropism. To address these obstacles, a variety of nonimmunogenic polymers are utilized to modify Ad vectors chemically or physically. In this review, we systemically discuss the functions of polymers in Ad-mediated gene delivery from two aspects: evading the host immune responses to Ads and redirecting Ad tropism. With polyethylene glycol (PEG) first in order, a variety of polymers have been developed to shield the surface of Ad vectors and well accomplished to evade the host immune response, block CAR-dependant cellular uptake, and reduce accumulation in the liver. In addition, shielding Ad vectors with targeted polymers (including targeting ligand-conjugated polymers and bio-responsive polymers) can also efficiently retarget Ad vectors to tumor tissues and reduce their distribution in nontargeted tissues. With its potential to evade the immune response and retarget Ad vectors, modification with polymers has been generally regarded as a promising strategy to facilitate the clinical applications of Ad vectors for virotherapy. STATEMENT OF SIGNIFICANCE: There is no doubt that Adenovirus (Ads) are attractive vectors for gene therapy, with high sophistication and effectiveness in overcoming both extra- and intracellular barriers, which cannot be exceeded by any other nonviral gene vectors. Unfortunately, their clinical applications are still restricted by some critical hurdles, including immunogenicity and native broad tropism. Therefore, a variety of elegant strategies have been developed from various angles to address these hurdles. Among these various strategies, coating Ads with nonimmunogenic polymers has attracted much attention. In this review, we systemically discuss the functions of polymers in Ad-mediated gene delivery from two aspects: evading the host immune responses to Ads and redirecting Ad tropism. In addition, the key factors in Ad modification with polymers have been highlighted and summarized to provide guiding theory for the design of more effective and safer polymer-Ad hybrid gene vectors.

[1]  Y. Yoshioka,et al.  Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[2]  E. Kang,et al.  Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Young Sook Lee,et al.  Oncolytic Adenovirus Coated with Multidegradable Bioreducible Core-Cross-Linked Polyethylenimine for Cancer Gene Therapy. , 2015, Biomacromolecules.

[4]  K. Ulbrich,et al.  Nanotherapeutics shielded with a pH responsive polymeric layer. , 2015, Physiological research.

[5]  H. Romanczuk,et al.  Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. , 1999, Human gene therapy.

[6]  James M. Wilson,et al.  “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.

[7]  E. Kang,et al.  Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity. , 2010, BMB reports.

[8]  I. McNeish,et al.  Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors , 2010, Viruses.

[9]  M. Betts,et al.  Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. , 2010, Vaccine.

[10]  Xun Sun,et al.  Bio-inspired polymer envelopes around adenoviral vectors to reduce immunogenicity and improve in vivo kinetics. , 2016, Acta biomaterialia.

[11]  S. Gambhir,et al.  In Vivo Bioluminescence Tumor Imaging of RGD Peptide-modified Adenoviral Vector Encoding Firefly Luciferase Reporter Gene , 2007, Molecular Imaging and Biology.

[12]  U. Greber,et al.  Innate immunity to adenovirus. , 2014, Human gene therapy.

[13]  A. Gaggar,et al.  CD46 is a cellular receptor for group B adenoviruses , 2003, Nature Medicine.

[14]  M. Rots,et al.  A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. , 2004, Human gene therapy.

[15]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[16]  S. Kochanek,et al.  Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications. , 2010, Human gene therapy.

[17]  M. Barry,et al.  Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  T. Möller,et al.  Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14 , 2010, Nature Medicine.

[19]  Martin L Read,et al.  Enhanced gene transfer activity of peptide-targeted gene-delivery vectors , 2005, Journal of drug targeting.

[20]  Seong-Cheol Park,et al.  Targeted gene delivery of polyethyleneimine-grafted chitosan with RGD dendrimer peptide in αvβ3 integrin-overexpressing tumor cells. , 2017, Carbohydrate polymers.

[21]  Y. Yoshioka,et al.  Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  N. Hackett,et al.  Variability of Human Systemic Humoral Immune Responses to Adenovirus Gene Transfer Vectors Administered to Different Organs , 1999, Journal of Virology.

[23]  Teruhiko Yoshida,et al.  Recent advances in genetic modification of adenovirus vectors for cancer treatment , 2017, Cancer science.

[24]  Roberto Cattaneo,et al.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded , 2008, Nature Reviews Microbiology.

[25]  Therése L. Eriksson,et al.  The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis , 2011, Nature Medicine.

[26]  S. Dharmapuri,et al.  Engineered adenovirus serotypes for overcoming anti-vector immunity , 2009, Expert opinion on biological therapy.

[27]  Alberto Smith,et al.  Glycoviruses: chemical glycosylation retargets adenoviral gene transfer. , 2005, Angewandte Chemie.

[28]  You Han Bae,et al.  Recent progress in tumor pH targeting nanotechnology. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[29]  S. W. Kim,et al.  Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex. , 2013, Biomaterials.

[30]  Alan E. Smith,et al.  PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. , 1999, Human gene therapy.

[31]  Y. Yoshioka,et al.  Polyethyleneimine-coating enhances adenoviral transduction of mesenchymal stem cells. , 2014, Biochemical and biophysical research communications.

[32]  S. Gambhir,et al.  Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  S. W. Kim,et al.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. , 2012, Biomaterials.

[34]  S. Gordon,et al.  Scavenger receptor A: a new route for adenovirus 5. , 2009, Molecular pharmaceutics.

[35]  C. Pouton,et al.  Adenovirus: a blueprint for non-viral gene delivery. , 2010, Current opinion in biotechnology.

[36]  A. Beaudet,et al.  PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile , 2005, Gene Therapy.

[37]  F. Graham,et al.  Methods for construction of adenovirus vectors , 1995, Molecular biotechnology.

[38]  E. Garrett-Mayer,et al.  Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[39]  S. W. Kim,et al.  Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. , 2011, Biomaterials.

[40]  A. Amalfitano,et al.  Improving Adenovirus Based Gene Transfer: Strategies to Accomplish Immune Evasion , 2010, Viruses.

[41]  R. Huebner,et al.  Isolation of a Cytopathogenic Agent from Human Adenoids Undergoing Spontaneous Degeneration in Tissue Culture , 1953, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[42]  Joo‐Hang Kim,et al.  Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[43]  D. Henaff,et al.  Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus) , 2011, Gene Therapy.

[44]  G. Dickson,et al.  Cationic Lipids and Polymers Are Able to Enhance Adenoviral Infection of Cultured Mouse Myotubes , 1999, Journal of neurochemistry.

[45]  M. Barry,et al.  Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers , 2016, Molecular therapy oncolytics.

[46]  H. Mizuguchi,et al.  Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro. , 2002, Biomaterials.

[47]  S. W. Kim,et al.  Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration. , 2011, Biomaterials.

[48]  K. Ulbrich,et al.  Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via α6-integrins , 2007, Cancer Gene Therapy.

[49]  A. Amalfitano,et al.  Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors , 2009, Expert opinion on biological therapy.

[50]  A. Pavirani,et al.  Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus‐induced Ig subclass shifts , 1997, European journal of immunology.

[51]  V. Šubr,et al.  E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells , 2011, Journal of drug targeting.

[52]  Sally Lehrman,et al.  Virus treatment questioned after gene therapy death , 1999, Nature.

[53]  K. Berg,et al.  Photochemically enhanced transduction of polymer‐complexed adenovirus targeted to the epidermal growth factor receptor , 2006, The journal of gene medicine.

[54]  S. W. Kim,et al.  Utilizing adenovirus vectors for gene delivery in cancer , 2014, Expert opinion on drug delivery.

[55]  S. W. Kim,et al.  Tuning Surface Charge and PEGylation of Biocompatible Polymers for Efficient Delivery of Nucleic Acid or Adenoviral Vector. , 2015, Bioconjugate chemistry.

[56]  S. Wadsworth,et al.  Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  K. Ulbrich,et al.  Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus , 2004, Gene Therapy.

[58]  James M. Wilson,et al.  PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. , 2002, Human gene therapy.

[59]  S. W. Kim,et al.  The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. , 2010, Biomaterials.

[60]  J. Atkinson,et al.  CD46 Is a Cellular Receptor for All Species B Adenoviruses except Types 3 and 7 , 2005, Journal of Virology.

[61]  K. Ulbrich,et al.  Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  Omid C Farokhzad,et al.  Insight into nanoparticle cellular uptake and intracellular targeting. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[63]  S. Kochanek,et al.  Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  P. Lu,et al.  Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. , 2009, Molecular pharmaceutics.

[65]  T. Park,et al.  Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[66]  K. Ulbrich,et al.  Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy , 2007, Journal of drug targeting.

[67]  S. W. Kim,et al.  Safety Profiles and Antitumor Efficacy of Oncolytic Adenovirus Coated with Bioreducible Polymer in the Treatment of a CAR Negative Tumor Model , 2014, Biomacromolecules.

[68]  Y. Yoshioka,et al.  Development of PEGylated adenovirus vector with targeting ligand. , 2008, International journal of pharmaceutics.

[69]  Hui-yong Xu,et al.  The Targeted Transduction of MMP-Overexpressing Tumor Cells by ACPP-HPMA Copolymer-Coated Adenovirus Conjugates , 2014, PloS one.

[70]  D. Collen,et al.  Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. , 2005, Human gene therapy.

[71]  P. Stewart,et al.  Insights into Adenovirus Uncoating from Interactions with Integrins and Mediators of Host Immunity , 2016, Viruses.

[72]  S. Nakagawa,et al.  Current targeting strategies for adenovirus vectors in cancer gene therapy. , 2011, Current cancer drug targets.

[73]  M. Barry,et al.  Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. , 2009, Human gene therapy.

[74]  Erkki Ruoslahti,et al.  Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins , 1995, Bio/Technology.

[75]  Florian Kreppel,et al.  Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  K. Ulbrich,et al.  Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker , 2010, Pharmaceutical Research.

[77]  M. Barry,et al.  Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. , 2008, Human gene therapy.

[78]  K. Ulbrich,et al.  Traceless Bioresponsive Shielding of Adenovirus Hexon with HPMA Copolymers Maintains Transduction Capacity In Vitro and In Vivo , 2014, PloS one.

[79]  R. Tsien,et al.  Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases , 2010, Proceedings of the National Academy of Sciences.

[80]  F. McCormick,et al.  Integrin αvβ5 is a primary receptor for adenovirus in CAR-negative cells , 2010, Virology Journal.

[81]  H. Mizuguchi,et al.  Targeted adenovirus vectors. , 2004, Human gene therapy.

[82]  S. W. Kim,et al.  Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. , 2014, Biomaterials.

[83]  Y. Tsutsumi,et al.  PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability , 2005, The journal of gene medicine.

[84]  H. Ertl,et al.  New insights on adenovirus as vaccine vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  S. W. Kim,et al.  Evolution of oncolytic adenovirus for cancer treatment. , 2012, Advanced drug delivery reviews.

[86]  T. Park,et al.  Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. , 2008, Biochemical and biophysical research communications.

[87]  S. Kochanek,et al.  Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  B. Kowtharapu,et al.  Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In Vivo , 2013, PloS one.

[89]  Z. Hartman,et al.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. , 2008, Virus research.

[90]  Nouri Nayerossadat,et al.  Viral and nonviral delivery systems for gene delivery , 2012, Advanced biomedical research.

[91]  Joung-Woo Choi,et al.  pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[92]  B. Walker,et al.  Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.

[93]  J. Wolff,et al.  Breaking the bonds: non-viral vectors become chemically dynamic. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[94]  M. Ogris,et al.  Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. , 2013, Molecular pharmaceutics.

[95]  J. Wilson,et al.  Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. , 2000, Human gene therapy.

[96]  Y. Yoshioka,et al.  Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis , 2009, Gene Therapy.

[97]  S. Kehoe,et al.  Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. , 2008, Human gene therapy.

[98]  M. Barry,et al.  Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[99]  K. Ulbrich,et al.  Retargeting polymer‐coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer , 2008, The journal of gene medicine.

[100]  Y. Bae,et al.  Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration. , 2015, Acta biomaterialia.

[101]  H. Herschman,et al.  The influence of innate and pre‐existing immunity on adenovirus therapy , 2009, Journal of cellular biochemistry.

[102]  Samuel K Lai,et al.  Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population. , 2016, Analytical chemistry.

[103]  T. Shimada,et al.  Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions , 2011, Gene Therapy.

[104]  Y. Nakayama,et al.  Enhancement of star vector-based gene delivery to endothelial cells by addition of RGD-peptide. , 2008, Bioconjugate chemistry.

[105]  Jung Min Lee,et al.  Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[106]  M. Croyle,et al.  PEGylated Adenoviruses: From Mice to Monkeys , 2010, Viruses.

[107]  X. Bian,et al.  Functional characterization of a PEI-CyD-FA-coated adenovirus as delivery vector for gene therapy. , 2013, Current medicinal chemistry.

[108]  N. Arnberg.  Adenovirus receptors: implications for targeting of viral vectors. , 2012, Trends in pharmacological sciences.

[109]  J. Ødegård,et al.  The involvement of the docking protein Gab1 in mitogenic signalling induced by EGF and HGF in rat hepatocytes. , 2013, Biochimica et biophysica acta.

[110]  S. W. Kim,et al.  Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy. , 2016, Nanomedicine.

[111]  B. Davidson,et al.  Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[112]  J. Atkinson,et al.  Adenovirus Type 11 Uses CD46 as a Cellular Receptor , 2003, Journal of Virology.

[113]  N. Van Rooijen,et al.  Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer , 2008, Journal of Virology.

[114]  M. Schwaiger,et al.  Systemic Image-Guided Liver Cancer Radiovirotherapy Using Dendrimer-Coated Adenovirus Encoding the Sodium Iodide Symporter as Theranostic Gene , 2013, The Journal of Nuclear Medicine.

[115]  E. Kang,et al.  SMART ADENOVIRUS NANOCOMPLEXES FOR SYSTEMIC DELIVERY , 2010 .

[116]  L. Seymour,et al.  HPMA copolymers for masking and retargeting of therapeutic viruses. , 2010, Advanced drug delivery reviews.

[117]  R. Grose,et al.  Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. , 2015, Trends in cell biology.

[118]  M. Lusky,et al.  Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. , 1997, Immunology letters.

[119]  H. Mizuguchi,et al.  Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses , 2011, Pharmaceutics.

[120]  M. Stevenson,et al.  Cancer gene therapy with targeted adenoviruses , 2008 .

[121]  Jaw-Yuan Wang,et al.  Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes , 2018, Theranostics.

[122]  S. W. Kim,et al.  Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy , 2016, Expert opinion on drug delivery.

[123]  S. W. Kim,et al.  Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. , 2011, Biomaterials.

[124]  D. Curiel,et al.  Transductional targeting of adenovirus vectors for gene therapy , 2006, Cancer Gene Therapy.

[125]  A. Amalfitano,et al.  Immune Recognition of Gene Transfer Vectors: Focus on Adenovirus as a Paradigm , 2011, Front. Immun..

[126]  Phuong-Truc T. Pham,et al.  Polymers for viral gene delivery , 2008, Expert opinion on drug delivery.

[127]  S. W. Kim,et al.  Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus. , 2015, Biomaterials.

[128]  Jeffrey M. Sailstad,et al.  Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer , 2015, The Journal of allergy and clinical immunology.

[129]  R. Harris,et al.  Epidermal growth factor, from gene organization to bedside. , 2014, Seminars in cell & developmental biology.

[130]  A E Smith,et al.  Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. , 1998, Human gene therapy.

[131]  N. Itoh,et al.  The Fibroblast Growth Factor signaling pathway , 2015, Wiley interdisciplinary reviews. Developmental biology.

[132]  H. Ertl,et al.  Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector. , 2011, The Journal of infectious diseases.

[133]  Jianfeng Han,et al.  Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus , 2012, International journal of nanomedicine.

[134]  Miriam Scadeng,et al.  Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival , 2010, Proceedings of the National Academy of Sciences.

[135]  Kumar Singarapu,et al.  Polyethylene glycol-grafted polyethylenimine used to enhance adenovirus gene delivery. , 2013, Journal of biomedical materials research. Part A.

[136]  K. Ulbrich,et al.  Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies , 2001, Gene Therapy.

[137]  E. Cavalletti,et al.  Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains. , 1994, Arzneimittel-Forschung.

[138]  I. Endo,et al.  Imaging and Antitumoral Effect of a Cyclo-oxygenase 2-specific Replicative Adenovirus for Small Metastatic Gastric Cancer Lesions. , 2015, Anticancer research.

[139]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[140]  B. Pitt,et al.  Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro , 1997, Gene Therapy.

[141]  Young Sook Lee,et al.  Polymeric oncolytic adenovirus for cancer gene therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[142]  C. Yun,et al.  Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer , 2014, Gene Therapy.

[143]  F. Kühnel,et al.  Oncolytic viruses: adenoviruses , 2017, Virus Genes.

[144]  A. Bowie,et al.  Sensing and Signaling in Antiviral Innate Immunity , 2010, Current Biology.